Sickle Cell Disease Survival Gains Reveal an Overlooked Midlife Crisis: Early Menopause

For most of modern medical history, sickle cell disease was considered a childhood illness, and for a tragic reason: few patients lived long enough to grow old with it. That picture is changing fast. Thanks to newborn screening, vaccination programs, hydroxyurea therapy, chronic transfusion strategies, and comprehensive care networks, survival has improved dramatically, and an estimated 7.74 million people worldwide were living with the disease in 2021. A growing share of them are women now reaching their forties and fifties, and a new Perspective published in Frontiers in Epidemiology argues that medicine is dangerously unprepared for what happens to these women at midlife, above all the menopausal transition.

The paper, authored by researchers at the University of Illinois Chicago, the University of Chicago, and the University of Miami Health System, proposes a lifespan framework for women’s health in sickle cell disease that stretches from menarche through menopause and into healthy aging. Its central claim is provocative: while fertility and pregnancy have received increasing attention as patients survive longer, menopause remains an underexplored and underrecognized phase of the disease trajectory, one that may shape pain, cognition, bone strength, cardiovascular risk, iron burden, and quality of life for decades.

To understand why menopause matters so much in this population, it helps to revisit the biology. Sickle cell disease stems from a single nucleotide substitution in the beta-globin gene that produces hemoglobin S. Under low-oxygen conditions, this hemoglobin polymerizes, forcing red blood cells into rigid, crescent shapes. These sickled cells are less deformable, stick to the vascular endothelium, and clog small vessels, producing the hallmark vaso-occlusive pain crises. Repeated sickling also damages cell membranes, driving chronic hemolysis, which in turn depletes nitric oxide, fuels oxidative stress, and sustains endothelial dysfunction and inflammation. The result is a multisystem disorder in which overlapping mechanisms inflict cumulative organ injury beginning in childhood.

That cumulative injury has led some researchers to describe sickle cell disease as a form of accelerated biological aging. The lungs are vulnerable to acute chest syndrome, pulmonary embolism, and pulmonary hypertension. Kidney damage can begin with tubular dysfunction in childhood and progress to chronic kidney disease in adolescence and adulthood. Cerebrovascular injury, from silent cerebral infarction to overt stroke, erodes cognition and quality of life. Against this backdrop, the authors argue, reproductive aging is not a separate process but another manifestation of aging that deserves a place alongside the rest.

Female physiology adds further layers of complexity. Although the disease arises from a single mutation, its severity is modified by genetics, including variants regulating fetal hemoglobin such as those affecting BCL11A, co-inherited alpha-thalassemia, APOL1 kidney risk variants, and pathways involved in oxidative stress and inflammation. Environmental exposures such as air pollution, secondhand smoke, and psychosocial stress worsen outcomes. And female-specific states modulate disease directly: menstruation can precipitate vaso-occlusive pain episodes beginning at menarche, hormonal fluctuations across the cycle influence vascular tone and inflammatory balance, hormonal contraceptives may alter thrombotic risk, and pregnancy, with its increased oxygen demand and prothrombotic state, amplifies the underlying vasculopathy.

Historically, clinical attention to reproduction in sickle cell disease has clustered around two moments: preserving fertility and managing pregnancy. Both matter. Hypoxic-ischemic injury, chronic inflammation, and gonadal exposure to disease-modifying therapies or transplant conditioning can diminish ovarian reserve. Pregnancy carries heightened risks of vaso-occlusive complications, acute chest syndrome, thromboembolism, preeclampsia, and medically indicated preterm delivery, and treatment decisions during pregnancy remain hampered by gaps in evidence. But the authors contend that this framing treats reproductive health as a series of isolated episodes rather than a continuous life course, and that the continuum does not end with pregnancy. It transitions into midlife, where the evidence is thinnest.

What evidence exists suggests that menopause arrives early. A Brazilian cohort reported menopause roughly five years earlier than expected in the general population, at approximately 46 to 48 years of age, and more recent observational studies from U.S. cohorts have similarly reported mean ages in the mid-to-late forties. These findings come with heavy caveats: small samples, single-center designs, and retrospective data collection that invites recall bias. Larger prospective studies are needed to determine whether reproductive aging is consistently accelerated, and whether timing differs by genotype, disease severity, or treatment exposure. Still, the signal is strong enough that the authors argue menopause should be treated as a critical component of comprehensive sickle cell care.

The midlife picture is more complicated than a simple worsening. In one cohort, up to 80 percent of women reported a reduction in vaso-occlusive pain frequency after menopause, raising the possibility that hormonal changes influence pain pathways, though the authors caution this should not be read as evidence that menopause consistently improves disease-related pain. Meanwhile, vasomotor symptoms, sleep disturbance, mood changes, anxiety, and fatigue may emerge or intensify during the transition, and because many of these overlap with core manifestations of sickle cell disease, menopause-related morbidity risks being misattributed entirely to the underlying condition, leading to underdiagnosis and undertreatment.

Treatment raises its own unresolved questions. Menopausal hormone therapy is the most effective treatment for vasomotor symptoms and has established indications for women with premature or early menopause, but there are currently no adequately powered clinical trials evaluating its safety, efficacy, or optimal formulation and duration in women with sickle cell disease. Because the disease is characterized by endothelial dysfunction, inflammation, and a prothrombotic state, thrombosis is an obvious concern, yet the authors stress that whether hormone therapy adds clinically meaningful thrombotic risk in this population has not been established; it is an important clinical question, not a demonstrated contraindication. Genitourinary syndrome of menopause, with its vaginal dryness, dyspareunia, and urinary symptoms, is another likely under-recognized burden, and low-dose vaginal estrogen, which has minimal systemic absorption, has not been evaluated in these patients.

Beyond symptoms, menopause may intersect with organ systems already compromised by the disease. Estrogen decline accelerates bone resorption, compounding skeletal vulnerability from chronic inflammation, marrow hyperplasia, vitamin D deficiency, and delayed puberty. Cessation of menstruation eliminates a physiologic route of iron loss, and emerging observations suggest iron indices may rise after menopause even after accounting for transfusion history, a particular concern for women with transfusion exposure. Cognitive health presents perhaps the most striking intersection: women with sickle cell disease may enter the menopausal transition carrying pre-existing neurovascular vulnerability from chronic anemia, cerebral hypoxia, and silent infarcts, so midlife hormonal changes unfold under far higher neurological risk than in the general population. Frailty and functional decline, the authors hypothesize, may likewise accelerate when menopause-related changes land on decades of disease-related physiologic stress.

The equity dimensions are hard to ignore. Sickle cell disease disproportionately affects populations in sub-Saharan Africa, the Middle East, India, and parts of the Americas, precisely the regions where access to comprehensive chronic disease management, reproductive health services, and menopause care is most variable. Even in resource-rich settings, care is fragmented between hematology, obstetrics, gynecology, and primary care; menopause may fall outside hematologists’ traditional scope, while menopause clinicians may have little experience with the disease. In low- and middle-income settings, structured menopause care may be entirely absent from routine services, meaning women enter midlife without any systematic assessment of symptoms or surveillance for bone, cardiovascular, cognitive, and functional decline.

The authors’ prescription is a coordinated lifespan model: routine screening for menstrual changes, vasomotor symptoms, sleep, mood, fatigue, genitourinary symptoms, and sexual health as women approach midlife; careful attribution of new or changing symptoms to both disease and menopause rather than defaulting to the disease alone; individualized hormone therapy decisions weighing genotype, prior venous thromboembolism, and vascular risk; and referral pathways connecting sickle cell specialists with menopause expertise. They also call for research priorities spanning prospective cohorts tracking age at menopause, genotype-stratified analyses, trials of menopause therapies, cognitive and neuroimaging studies, and implementation research adapted to local resources rather than assuming one multidisciplinary model fits all settings.

The stakes extend beyond any single clinic. As survival improves, the measure of success for a lifelong genetic disease can no longer be simply keeping children alive; it must be whether those children grow into adults who age well. Integrating reproductive aging into clinical practice, research agendas, and health policy, the authors argue, is an opportunity to strengthen women-centered care and advance health equity for the millions of women worldwide living with sickle cell disease. Menopause, long invisible in the sickle cell literature, may turn out to be one of the most consequential frontiers in the field.

Subject of Research: Menopause and reproductive aging in women with sickle cell disease across the lifespan

Article Title: From menarche to menopause: a lifespan perspective on women's health in sickle cell disease

Article References: Farooqui, M., Christmas, M., Goba, G., & Hsu, L. (2026). From menarche to menopause: a lifespan perspective on women's health in sickle cell disease. Frontiers in Epidemiology, 6, Article 1931488. https://doi.org/10.3389/fepid.2026.1931488

Image Credits: AI Generated

DOI: 10.3389/fepid.2026.1931488

Keywords: sickle cell disease, menopause, women's health, reproductive aging, menopausal hormone therapy, vaso-occlusive pain, health equity, bone health, cognitive health, iron overload, cardiovascular risk, lifespan care